FastWave: The Next Generation of
Intravascular Lithotripsy (IVL)

FastWave: The Next Generation of Intravascular Lithotripsy (IVL)

FastWave: The Next Generation of Intravascular Lithotripsy (IVL)

Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.

Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.

Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.

Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

1 in 4 deaths in the U.S. is caused by CAD.¹

1 in 4 deaths in the U.S. is caused by CAD.¹

1 in 4 deaths in the U.S. is caused by CAD.¹

Every year, CAD causes 17.8 million deaths globally.¹

Every year, CAD causes 17.8 million deaths globally.¹

Every year, CAD causes 17.8 million deaths globally.¹

A limb is amputated every 3-5 minutes in the U.S.²

A limb is amputated every 3-5 minutes in the U.S.²

A limb is amputated every 3-5 minutes in the U.S.²

1 in 2 patients die from amputation within 1 year.³

1 in 2 patients die from amputation within 1 year.³

1 in 2 patients die from amputation within 1 year.³

Calcium is Highly Prevalent in CAD and PAD

Calcium is Highly Prevalent in CAD and PAD

Calcium is Highly Prevalent in CAD and PAD

Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with traditional interventional modalities.

We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools

Dr. Amir Kaki

Interventional Cardiologist

We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools

Dr. Amir Kaki

Interventional Cardiologist

We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools

Dr. Amir Kaki

Interventional Cardiologist

IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment

IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment

IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment

The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.⁵

FastWave is Empowering Physicians with Advanced IVL Technology

FastWave is Empowering Physicians with Advanced IVL Technology

FastWave is Empowering Physicians with Advanced IVL Technology

Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.

Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.

Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.

First-Generation IVL

Peripheral IVL

Coronary IVL

Ease of Use

Pulse Count Availability

Crossability & Deliverability

Consistent & Predictable Sonic Pressure

Balloon Lengths

360-degree Sonic Coverage

Learn More

Learn More

First-Generation IVL

First-Generation IVL

Ease of Use

Ease of Use

Pulse Count Availability

Pulse Count Availability

Crossability & Deliverability

Crossability & Deliverability

Consistent & Predictable Sonic Pressure

Consistent & Predictable Sonic Pressure

Balloon Lengths

Balloon Lengths

360-degree Sonic Coverage

360-degree Sonic Coverage

Peripheral IVL

Ease of Use

Ease of Use

Pulse Count Availability

Pulse Count Availability

Crossability & Deliverability

Crossability & Deliverability

Consistent & Predictable Sonic Pressure

Consistent & Predictable Sonic Pressure

Balloon Lengths

Balloon Lengths

360-degree Sonic Coverage

360-degree Sonic Coverage

Learn More

Learn More

Coronary IVL

Ease of Use

Ease of Use

Pulse Count Availability

Pulse Count Availability

Crossability & Deliverability

Crossability & Deliverability

Consistent & Predictable Sonic Pressure

Consistent & Predictable Sonic Pressure

Balloon Lengths

Balloon Lengths

360-degree Sonic Coverage

360-degree Sonic Coverage

Learn More

Learn More

Successful First-in-Human (FIH) Study

Successful First-in-Human (FIH) Study

Successful First-in-Human (FIH) Study

In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.

In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.

Study Overview

Study Overview

Investigators

Investigators

Drs. Miguel Montero-Banker, Venkatesh Ramaiah, and Antonio Muñoa

Drs. Miguel Montero-Banker, Venkatesh Ramaiah, and Antonio Muñoa

Location

Location

San Lucas Hospital, Chiapas, Mexico

San Lucas Hospital, Chiapas, Mexico

Dates

Dates

January 11-12, 2024

January 11-12, 2024

Study Results

Study Results

9 successfully treated limbs across 8 patients

9 successfully treated limbs across 8 patients

100% of lesions crossed, including 3 CTOs

100% of lesions crossed, including 3 CTOs

Post-treatment mean residual diameter stenosis of 5.5%

Post-treatment mean residual diameter stenosis of 5.5%

0% AEs with no balloon ruptures

0% AEs with no balloon ruptures

See More Evidence

See More Evidence

FastWave is Advancing at an Unparalleled Pace

FastWave is Advancing at an Unparalleled Pace

FastWave is Advancing at an Unparalleled Pace

February 2021

February 2021

FastWave established as a stand-alone Delaware C-corp.

FastWave established as a stand-alone Delaware C-corp.

FastWave established as a stand-alone Delaware C-corp.

August 2021

August 2021

FastWave raises $12M Series A round of financing.

FastWave raises $12M Series A round of financing.

FastWave raises $12M Series A round of financing.

November 2022

November 2022

USPTO grants FastWave its first utility patent within 6 months of filing.

USPTO grants FastWave its first utility patent within 6 months of filing.

USPTO grants FastWave its first utility patent within 6 months of filing.

April 2023

April 2023

USPTO grants FastWave its second IVL utility patent.

USPTO grants FastWave its second IVL utility patent.

USPTO grants FastWave its second IVL utility patent.

June 2023

June 2023

FastWave closes oversubscribed private financing round within a few weeks.

FastWave closes oversubscribed private financing round within a few weeks.

FastWave closes oversubscribed private financing round within a few weeks.

January 2024

January 2024

FastWave completes enrollment for the first-in-human study of its peripheral IVL system.

FastWave completes enrollment for the first-in-human study of its peripheral IVL system.

FastWave completes enrollment for the first-in-human study of its peripheral IVL system.

March, April, and May 2024

March, April, and May 2024

USPTO grants FastWave its third, fourth, and fifth IVL utility patents.

USPTO grants FastWave its third, fourth, and fifth IVL utility patents.

USPTO grants FastWave its third, fourth, and fifth IVL utility patents.

June 2024

June 2024

FastWave closes oversubscribed $19M financing round in less than a month.

FastWave closes oversubscribed $19M financing round in less than a month.

FastWave closes oversubscribed $19M financing round in less than a month.

December 2024

December 2024

USPTO grants FastWave its sixth IVL utility patent.

USPTO grants FastWave its sixth IVL utility patent.

USPTO grants FastWave its sixth IVL utility patent.

January 2025

January 2025

USPTO grants Fastwave its seventh IVL utility patent.

USPTO grants Fastwave its seventh IVL utility patent.

USPTO grants Fastwave its seventh IVL utility patent.

Meet our Founders

Meet our Founders

Meet our Founders

Scott Nelson

Co-Founder and CEO

Serial entrepreneur with 20 years of medtech & healthtech experience at multinational strategics and high-growth startups.

Scott Nelson

Co-Founder and CEO

Serial entrepreneur with 20 years of medtech & healthtech experience at multinational strategics and high-growth startups.

Scott Nelson

Co-Founder and CEO

Serial entrepreneur with 20 years of medtech & healthtech experience at multinational strategics and high-growth startups.

Brady Hatcher

Co-Founder and Director

Founder of 10+ medtech startups, inventor on dozens of issued patents, and catalyst for multiple successful company exits.

Brady Hatcher

Co-Founder and Director

Founder of 10+ medtech startups, inventor on dozens of issued patents, and catalyst for multiple successful company exits.

Brady Hatcher

Co-Founder and Director

Founder of 10+ medtech startups, inventor on dozens of issued patents, and catalyst for multiple successful company exits.

JC Sun, PhD, MBA

Co-Founder and Director

Extensive equity transaction experience with hundreds of millions in closings as sell-side advisor for many medtech startups.

JC Sun, PhD, MBA

Co-Founder and Director

Extensive equity transaction experience with hundreds of millions in closings as sell-side advisor for many medtech startups.

JC Sun, PhD, MBA

Co-Founder and Director

Extensive equity transaction experience with hundreds of millions in closings as sell-side advisor for many medtech startups.

See the Team

See the Team

See How You Can Invest in FastWave

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.

Dr. Puneet Khanna

Interventional Cardiologist & Medtech Investor

See How You Can Invest in FastWave

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.

Dr. Puneet Khanna

Interventional Cardiologist & Medtech Investor

See How You Can Invest in FastWave

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.

Dr. Puneet Khanna

Interventional Cardiologist & Medtech Investor

Mailing Address:

FastWave Medical
400 S 4th St, Ste 410
PMB 21892
Minneapolis, MN 55415

Phone:

(833) 888-9283

Email:

team@fastwavemedical.com

Follow FastWave’s Journey

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market

Mailing Address:

FastWave Medical
400 S 4th St, Ste 410
PMB 21892
Minneapolis, MN 55415

Phone:

(833) 888-9283

Email:

team@fastwavemedical.com

Follow FastWave’s Journey

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market

Mailing Address:

FastWave Medical
400 S 4th St, Ste 410
PMB 21892
Minneapolis, MN 55415

Phone:

(833) 888-9283

Email:

team@fastwavemedical.com

Follow FastWave’s Journey

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market